Advanced methods in Cancer Immunotherapy
Assessing the global challenges inhibiting immuno-oncology market access.
Latest innovations emerging from immunotherapy research
Learn innovative solutions to address these challenges
Collaborate with CROs and sites to help minimize risks
German Merck has option to licence LAG3-PDL1 drug.
The cancer challenge is affecting more and more people worldwide, with 21 million cases expected by 2030.
UK biotech pioneering new type of T cell immunotherapy